APA (7th ed.) Citation

T, Y., V, Z., A, S., M, A., SP, C., A, M., . . . F, P. (2023). Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(9), 1747. https://doi.org/10.1200/JCO.22.00972

Chicago Style (17th ed.) Citation

T, Yau, et al. "Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41, no. 9 (2023): 1747. https://doi.org/10.1200/JCO.22.00972.

MLA (9th ed.) Citation

T, Yau, et al. "Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 9, 2023, p. 1747, https://doi.org/10.1200/JCO.22.00972.